EQS News: Viromed Medical AG: cold plasma as a digital antibiotic for the lungs | 26.11.24

Viromed Medical AG: Cold plasma as a digital antibiotic for the lungs

• Innovative prevention measure for ventilator-associated pneumonia reaches the next phase
• The use of cold plasma could prevent tens of thousands of deaths in Germany alone
• Research led by expert from the renowned research network BREATH, Hortense Slevogt

Pinneberg, 26 November 2024 – Viromed Medical AG (ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) stimulates research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific leadership of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project investigates the safety and efficacy of cold plasma to kill bacteria in the respiratory tract, for approval as a therapy.

The official announcement from the BREATH research network about this was published on November 22, 2024.

The renowned expert network BREATH (biomedical Rresearch End phase Aand ObsTractive lung disease Hannover) is one of the five locations of the German Center for Pulmonary Research (DZL) and uniquely unites internationally recognized expertise in the field of translational respiratory medicine. The research network consists of the four strong partners Hannover Medical School, Leibniz Universität Hannover, Fraunhofer ITEM and CAPNETZ FOUNDATION.

VAP is a common and serious complication in mechanically ventilated patients, occurring in patients receiving invasive ventilation for at least 48 hours. Research shows that VAP affects 23-36% of mechanically ventilated patients and is associated with prolonged ventilation, prolonged intensive care unit and hospital stays, and an estimated mortality rate of 10-13%. In Germany alone, approximately 486,000 patients required mechanical ventilation in intensive care units in 2023, highlighting the need for VAP prevention measures.

Uwe Perbandt, CEO of Viromed Medical AG, explained: “Even in the past, people often did not die from injuries, but from the infections that followed. Today we are heading towards a similar scenario. Due to the increasing resistance of germs, many people can no longer be helped. An infection is synonymous with death. Moreover, in the human body it sometimes takes days for antibiotics to reach the source of the disease. With cold plasma we don’t have these problems. It can reach the site of infection in minutes and destroy pathogens – including those already resistant to antibiotics – just as quickly. The main advantage is that cold plasma physically destroys germs. And there can be no resistance to that. So if the efficacy and safety of cold plasma continues to be confirmed in the course of research, which I firmly believe will happen, we have here in effect a ‘digital antibiotic’ that will take us a major step forward in the future. fight against many diseases. In this way we can save tens or even hundreds of thousands of lives. In my opinion, this asset can significantly increase the value of the AG. Since BREATH published the news on Friday, we have already received numerous international inquiries.”

Prof. Dr. Hortense Slevogt, Clinic for Pneumology and Infectiology, MHH: “Ventilator-associated pneumonia not only has a high mortality rate, but also places a significant burden on the healthcare system due to increased antibiotic use, longer patient stays and higher treatment costs. The growing antibiotic resistance of pathogens makes new, non-antibiotic approaches urgently necessary. If the positive preliminary results of our study are confirmed, cold plasma could revolutionize the treatment of ventilated patients.”

About Viromed Medical AG:

Viromed Medical AG specializes in the development, production and distribution of medical products. The business activities of the company, which has been listed on the stock exchange since October 2022, focus on the distribution of innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region, including Dax companies such as Volkswagen and Lufthansa, state and federal authorities and ministries, as well as 1,100 hospitals, 7,000 pharmacies and 11,000 medical practices.

Cold atmospheric plasma (CAP) has been scientifically proven to inactivate harmful viruses, fungi and bacteria and has the potential to revolutionize conventional treatment methods in a wide range of areas. Viromed Medical AG is carrying out important pioneering work in this field. The clearly superior CAP is already used to treat difficult-healing wounds. Viromed is currently conducting clinical trials for use in pulmonary medicine. Viromed Medical AG is pursuing the goal of further promoting the use of CAP in medicine in the coming years and realizing the associated growth potential.

Please contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Strasse 18
25421 Pinneberg
Germany
Email: [email protected]
www.viromed-medical-ag.de